Phase 1 CLE Clinical Trials
229 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 229 trials
Recruiting
Phase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC23 enrolled5 locationsNCT07290062
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled8 locationsNCT07300241
Recruiting
Phase 1
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Phase 1Phase 2
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis(ALS)
Nura Bio80 enrolled4 locationsNCT07369076
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled12 locationsNCT04977453
Recruiting
Phase 1Phase 2
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1Phase 2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Vector Y Therapeutics12 enrolled11 locationsNCT07287397
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464
Recruiting
Phase 1Phase 2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 1Phase 2
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC235 enrolled59 locationsNCT05316155
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
HealthyIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Xencor, Inc.60 enrolled1 locationNCT07284797
Recruiting
Phase 1
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+3 more
City of Hope Medical Center33 enrolled2 locationsNCT07128680
Recruiting
Phase 1Phase 2
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)250 enrolled1 locationNCT03109288
Recruiting
Phase 1
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Multiple SclerosisProgressive Multifocal LeukoencephalopathyOther Neuroinflammatory Diseases With BBB Leakage
National Institute of Neurological Disorders and Stroke (NINDS)15 enrolled1 locationNCT05849467
Recruiting
Phase 1Phase 2
MB-CART2019.1 in Refractory Multiple Sclerosis
Multiple SclerosisCAR-T Cell Therapy
Miltenyi Biomedicine GmbH26 enrolled1 locationNCT07178431